The Global Health Body Raises Concern Over Severe Scarcity of Weight-Loss Injections
Under 10% of patients who could benefit from obesity jabs such as Wegovy can access them, states the World Health Organization as it publishes its first advice on the drugs.
Considering in excess of 1,000,000,000 individuals worldwide now obese, it is calling for more widespread and fairer access to these injectable treatments.
Per projections, over two billion are projected to be living with obesity by 2030 unless action is taken.
"Our new guidance affirms that obesity is a long-term condition that can be addressed with holistic and continuous support," said its chief Tedros Adhanom Ghebreyesus.
Substantial prices, insufficient output, and distribution challenges are significant barriers to widespread access to the treatments that can help people shift substantial weight, notes the organization.
GLP-1 Therapy Supply Crisis
Despite the current best projected scenario, the manufacturing of such drugs could only cover around 100 million people – less than 10% of eligible patients, per the health organization.
The advice encourages governments and firms to widen availability, by measures including voluntary licensing.
Exclusive production rights on the active ingredient – the primary component of a leading brand – is set to lapse in multiple nations in 2026.
The Way Weight-Loss Jabs Operate
These medications imitate a body's own hormone to delay gastric emptying, curb appetite and enhance the sense of being full so people eat less.
Patients usually see weight reduction within a few weeks of starting on the regular doses.
Studies indicates people may regain a significant portion within a year of halting the treatment, as their normal food cravings return.
To be above a healthy weight raises your risk for contracting diseases, including diabetes, heart disease, brain attack, and certain malignancies.
Excess weight affects individuals in all nations and was linked to millions of fatalities worldwide in 2024, as per the WHO.
